As of 30 June 2026, AstraZeneca PLC reported a total of 1,551,024,534 ordinary shares with voting rights. No shares are held in treasury. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines.

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) received European Union approval as a monotherapy for adult patients with unresectable or metastatic HER2-positive solid tumours who have received prior treatment. The approval is based on results from three Phase II trials: DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02. As a result of this approval, AstraZeneca will make a $25 million milestone payment to Daiichi Sankyo. AstraZeneca is a global biopharmaceutical company that develops and commercialises prescription medicines in oncology, rare disease, and biopharmaceuticals.

The CHMP of the European Medicines Agency has recommended Datroway (datopotamab deruxtecan) for approval as a 1st-line treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy. Based on the TROPION-Breast02 Phase III trial, Datroway demonstrated a 5.0-month improvement in median overall survival (23.7 months vs 18.7 months) and a 43% reduction in the risk of disease progression or death. AstraZeneca and Daiichi Sankyo jointly develop and commercialize Datroway; the drug is already approved in the US and in HR-positive, HER2-negative breast cancer. AstraZeneca is a global, science-led biopharmaceutical company focusing on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals.

On June 15, 2026, the US FDA approved Truqap (capivasertib) in combination with abiraterone and prednisone as the first targeted treatment for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive (mAPMN/S) prostate cancer. The approval follows the Phase III CAPItello-281 trial, which demonstrated a 19% reduction in the risk of radiographic disease progression or death (HR 0.81) and improved median radiographic progression-free survival to 33.2 months compared to 25.7 months for the control group. The FDA also approved a companion diagnostic test to detect PTEN deficiency. A similar regulatory application is currently under review in the EU. AstraZeneca is a global biopharmaceutical company that discovers, develops, and commercializes prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals.